Literature DB >> 23250757

The non-lysosomal β-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi.

Heinz G Körschen1, Yildiz Yildiz, Diana Nancy Raju, Sophie Schonauer, Wolfgang Bönigk, Vera Jansen, Elisabeth Kremmer, U Benjamin Kaupp, Dagmar Wachten.   

Abstract

GBA1 and GBA2 are both β-glucosidases, which cleave glucosylceramide (GlcCer) to glucose and ceramide. GlcCer is a main precursor for higher order glycosphingolipids but might also serve as intracellular messenger. Mutations in the lysosomal GBA1 underlie Gaucher disease, the most common lysosomal storage disease in humans. Knocking out the non-lysosomal GBA2 in mice results in accumulation of GlcCer outside the lysosomes in various tissues (e.g. testis and liver) and impairs sperm development and liver regeneration. However, the underlying mechanisms are not well understood. To reveal the physiological function of GBA2 and, thereby, of the non-lysosomal GlcCer pool, it is important to characterize the localization of GBA2 and its activity in different tissues. Thus, we generated GBA2-specific antibodies and developed an assay that discriminates between GBA1 and GBA2 without the use of detergent. We show that GBA2 is not, as previously thought, an integral membrane protein but rather a cytosolic protein that tightly associates with cellular membranes. The interaction with the membrane, in particular with phospholipids, is important for its activity. GBA2 is localized at the ER and Golgi, which puts GBA2 in a key position for a lysosome-independent route of GlcCer-dependent signaling. Furthermore, our results suggest that GBA2 might affect the phenotype of Gaucher disease, because GBA2 activity is reduced in Gba1 knock-out fibroblasts and fibroblasts from a Gaucher patient. Our results provide the basis to understand the mechanism for GBA2 function in vivo and might help to unravel the role of GBA2 during pathogenesis of Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23250757      PMCID: PMC3561557          DOI: 10.1074/jbc.M112.414714

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Pitfalls in the use of artificial substrates for the diagnosis of Gaucher's disease.

Authors:  Y Ben-Yoseph; H L Nadler
Journal:  J Clin Pathol       Date:  1978-11       Impact factor: 3.411

2.  Glucosidases.

Authors:  G Legler
Journal:  Methods Enzymol       Date:  1977       Impact factor: 1.600

3.  Gaucher's disease: deficiency of 'acid' -glucosidase and reconstitution of enzyme activity in vitro.

Authors:  M W Ho; J S O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  1971-11       Impact factor: 11.205

4.  Molecular cloning and expression of human bile acid beta-glucosidase.

Authors:  H Matern; H Boermans; F Lottspeich; S Matern
Journal:  J Biol Chem       Date:  2001-08-06       Impact factor: 5.157

5.  Cell-specific differences in membrane beta-glucosidase from normal and Gaucher cells.

Authors:  B M Turner; N G Beratis; K Hirschhorn
Journal:  Biochim Biophys Acta       Date:  1977-02-09

6.  Molecular cloning and expression of a novel klotho-related protein.

Authors:  K Yahata; K Mori; H Arai; S Koide; Y Ogawa; M Mukoyama; A Sugawara; S Ozaki; I Tanaka; Y Nabeshima; K Nakao
Journal:  J Mol Med (Berl)       Date:  2000       Impact factor: 4.599

7.  Properties of beta-glucosidase in cultured skin fibroblasts from controls and patients with Gaucher disease.

Authors:  B M Turner; K Hirschhorn
Journal:  Am J Hum Genet       Date:  1978-07       Impact factor: 11.025

8.  Identification of a family of animal sphingomyelin synthases.

Authors:  Klazien Huitema; Joep van den Dikkenberg; Jos F H M Brouwers; Joost C M Holthuis
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

9.  Twin pairs showing discordance of phenotype in adult Gaucher's disease.

Authors:  R H Lachmann; I R Grant; D Halsall; T M Cox
Journal:  QJM       Date:  2004-04

10.  Cell surface associated glycohydrolases in normal and Gaucher disease fibroblasts.

Authors:  Massimo Aureli; Rosaria Bassi; Nicoletta Loberto; Stefano Regis; Alessandro Prinetti; Vanna Chigorno; Johannes M Aerts; Rolf G Boot; Mirella Filocamo; Sandro Sonnino
Journal:  J Inherit Metab Dis       Date:  2012-04-19       Impact factor: 4.982

View more
  35 in total

Review 1.  Current and Novel Aspects on the Non-lysosomal β-Glucosylceramidase GBA2.

Authors:  Aureli Massimo; Samarani Maura; Loberto Nicoletta; Mancini Giulia; Murdica Valentina; Chiricozzi Elena; Prinetti Alessandro; Bassi Rosaria; Sonnino Sandro
Journal:  Neurochem Res       Date:  2015-11-24       Impact factor: 3.996

2.  AMP-activated Protein Kinase Suppresses Biosynthesis of Glucosylceramide by Reducing Intracellular Sugar Nucleotides.

Authors:  Yohei Ishibashi; Yoshio Hirabayashi
Journal:  J Biol Chem       Date:  2015-06-05       Impact factor: 5.157

Review 3.  Exploring the link between ceramide and ionizing radiation.

Authors:  Massimo Aureli; Valentina Murdica; Nicoletta Loberto; Maura Samarani; Alessandro Prinetti; Rosaria Bassi; Sandro Sonnino
Journal:  Glycoconj J       Date:  2014-10       Impact factor: 2.916

4.  Mutations in CYP2U1, DDHD2 and GBA2 genes are rare causes of complicated forms of hereditary spastic paraparesis.

Authors:  Andrea Citterio; Alessia Arnoldi; Elena Panzeri; Maria Grazia D'Angelo; Massimiliano Filosto; Robertino Dilena; Filippo Arrigoni; Marianna Castelli; Cristina Maghini; Chiara Germiniasi; Francesca Menni; Andrea Martinuzzi; Nereo Bresolin; Maria Teresa Bassi
Journal:  J Neurol       Date:  2013-12-13       Impact factor: 4.849

5.  The Arabidopsis AtGCD3 protein is a glucosylceramidase that preferentially hydrolyzes long-acyl-chain glucosylceramides.

Authors:  Guang-Yi Dai; Jian Yin; Kai-En Li; Ding-Kang Chen; Zhe Liu; Fang-Cheng Bi; Chan Rong; Nan Yao
Journal:  J Biol Chem       Date:  2019-12-08       Impact factor: 5.157

6.  β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology.

Authors:  Christina M Ridley; Karen E Thur; Jessica Shanahan; Nagendra Babu Thillaiappan; Ann Shen; Karly Uhl; Charlotte M Walden; Ahad A Rahim; Simon N Waddington; Frances M Platt; Aarnoud C van der Spoel
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

7.  Functional and pharmacological induced structural changes of the cystic fibrosis transmembrane conductance regulator in the membrane solved using SAXS.

Authors:  Debora Baroni; Olga Zegarra-Moran; Oscar Moran
Journal:  Cell Mol Life Sci       Date:  2014-10-02       Impact factor: 9.261

Review 8.  The glycosphingolipid hydrolases in the central nervous system.

Authors:  Massimo Aureli; Maura Samarani; Nicoletta Loberto; Rosaria Bassi; Valentina Murdica; Simona Prioni; Alessandro Prinetti; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2013-11-27       Impact factor: 5.590

9.  Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.

Authors:  Fredj Ben Bdira; Marta Artola; Herman S Overkleeft; Marcellus Ubbink; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2018-10-02       Impact factor: 5.922

10.  Role of β-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish.

Authors:  Lindsey T Lelieveld; Mina Mirzaian; Chi-Lin Kuo; Marta Artola; Maria J Ferraz; Remco E A Peter; Hisako Akiyama; Peter Greimel; Richard J B H N van den Berg; Herman S Overkleeft; Rolf G Boot; Annemarie H Meijer; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2019-09-27       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.